Free accessCase reportFirst published online 2011-2
Transmission of Integrase Strand-Transfer Inhibitor Multidrug-Resistant HIV-1: Case Report and Response to Raltegravir-Containing Antiretroviral Therapy
We report the case of an integrase strand-transfer inhibitor (INI)-resistant and four-drug-class-resistant HIV-1 variant infecting an antiretroviral therapy-naive man. The virus harboured INI drug resistance substitutions (Q148H and G140S) along with multiple reverse transcriptase and protease inhibitor resistance mutations. This case illustrates an emerging need to consider the possibility of acquired INI resistance among newly diagnosed treatment-naive individuals harbouring multidrug-resistant HIV-1.
References
1.
GrantR.M., HechtF.M., WarmerdamM.Time trends in primary HIV-1 drug resistance among recently infected persons. JAMA2002; 288: 181–188.
2.
GerettiA.M.Epidemiology of antiretroviral drug resistance in drug-naive persons. Curr Opin Infect Dis2007; 20: 22–32.
3.
LittleS.J., HolteS., RoutyJ.P.Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med2002; 347: 385–394.
4.
DHHS Panel on Antiretroviral Guidelines for Adults and Adolescents.Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. US Department of Health and Human Services; 2011. (Updated 10 January 2011. Accessed 1 February 2011.) Available from http://www.aidsinfo.nih.gov/ContentFiles/AdultandAdolescentGL.pdf.
5.
EriceA., MayersD.L., StrikeD.G.Brief report: primary infection with zidovudine-resistant human immunodeficiency virus type 1. N Engl J Med1993; 328: 1163–1165.
6.
ImrieA., BeveridgeA., GennW., VizzardJ., CooperD.A.Transmission of human immunodeficiency virus type 1 resistant to nevirapine and zidovudine. Sydney Primary HIV Infection Study Group. J Infect Dis1997; 175: 1502–1506.
7.
HechtF.M., GrantR.M., PetropoulosC.J.Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. N Engl J Med1998; 339: 307–311.
8.
LittleS.J., DaarE.S., D'AquilaR.T.Reduced antiretroviral drug susceptibility among patients with primary HIV infection. JAMA1999; 282: 1142–1149.
9.
PetropoulosC.J., ParkinN.T., LimoliK.L.A novel phenotypic drug susceptibility assay for human immunodeficiency virus type 1. Antimicrob Agents Chemother2000; 44: 920–928.
10.
Ceccherini-SilbersteinF., MaletI., FabeniL.Specific HIV-1 integrase polymorphisms change their prevalence in untreated versus antiretroviral-treated HIV-1 infected patients, naive to integrase inhibitors. J Antimicrob Chemother2010; 65: 2305–2318.
11.
FransenS., GuptaS., DanovichR.Loss of raltegravir susceptibility by human immunodeficiency virus type 1 is conferred via multiple nonoverlapping genetic pathways. J Virol2009; 83: 11440–11446.
12.
HatanoH., LampirisH., FransenS.Evolution of integrase resistance during failure of integrase inhibitor-based antiretroviral therapy. J Acquir Immune Defic Syndr2010; 54: 389–393.
13.
FransenS., KarmochkineM., HuangW., WeissL., PetropoulosC.J., CharpentierC.Longitudinal analysis of raltegravir susceptibility and integrase replication capacity of human immunodeficiency virus type 1 during virologic failure. Antimicrob Agents Chemother2009; 53: 4522–4524.
14.
DelelisO., ThierryS., SubraF.Impact of Y143 HIV-1 integrase mutations on resistance to raltegravir in vitro and in vivo. Antimicrob Agents Chemother2010; 54: 491–501.
15.
DelelisO., MaletI., NaL.The G140S mutation in HIV integrases from raltegravir-resistant patients rescues catalytic defect due to the resistance Q148H mutation. Nucleic Acids Res2009; 37: 1193–1201.
16.
JohnsonV.A., Brun-VézinetF., ClotetB.Update of the drug resistance mutations in HIV-1: December 2009. Top HIV Med2009; 17: 138–145.
